BIOA
BioAge Labs Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth n/a ·
share flow n/a ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 256 | $1,742 | n/a | n/a |
| Q2 2026 | 66 | +4 | 13.22M | $323.71M | +6 | −2 |
| Q1 2026 | 65 | +14 | 13.97M | $243.82M | +19 | −5 |
| Q4 2025 | 51 | +2 | 8.60M | $113.77M | +2 | n/a |
| Q3 2025 | 16 | +1 | 5.16M | $30.36M | +1 | n/a |
| Q2 2025 | 12 | +5 | 4.16M | $17.19M | +5 | n/a |
| Q1 2025 | 4 | 0 | 455.40K | $1.71M | +2 | −2 |
| Q4 2024 | 4 | -5 | 347.20K | $2.01M | +1 | −6 |
| Q3 2024 | 8 | +8 | 1.18M | $24.62M | +8 | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 449.84K | New | $9.36M | 0.0% | New | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 213.72K | New | $4.45M | 0.0% | New | 1 | SEC ↗ |
| 3 | Marshall Wace ✦ | 200.00K | New | $4.16M | 0.0% | New | 1 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 166.02K | New | $3.45M | 0.0% | New | 1 | SEC ↗ |
| 5 | Soros Fund Management ✦ | 100.00K | New | $2.08M | 0.1% | New | 1 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 40.00K | New | $832,000 | 0.0% | New | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 11.50K | New | $239,200 | 0.0% | New | 1 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 2.70K | New | $56,160 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| T. Rowe Price | $9.36M | 0.0% |
| Citadel Advisors | $4.45M | 0.0% |
| Marshall Wace | $4.16M | 0.0% |
| Millennium Management | $3.45M | 0.0% |
| Soros Fund Management | $2.08M | 0.1% |
| Norges Bank | $832,000 | 0.0% |
| Two Sigma Investments | $239,200 | 0.0% |
| Point72 Asset Management | $56,160 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 143 holders, 34.12M shares, $588.17M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.